Detection and Genotyping of Varicella-Zoster Virus by TaqMan Allelic Discrimination Real-Time PCR

Paul A. Campsall, Nicholas H. C. Au, Julie S. Prendiville, David P. Speert, Rusung Tan, and Eva E. Thomas

Department of Pathology and Laboratory Medicine and Division of Pediatric Dermatology, Department of Pediatrics, University of British Columbia and Children’s & Women’s Health Centre of British Columbia, and Division of Infectious and Immunological Diseases, Department of Pediatrics and the British Columbia Research Institute for Children’s and Women’s Health, University of British Columbia, Vancouver, British Columbia, Canada

Received 15 September 2003/Returned for modification 21 October 2003/Accepted 6 November 2003

A proportion of individuals vaccinated with live attenuated Oka varicella-zoster virus (VZV) vaccine subsequently develop attenuated chicken pox and/or herpes zoster. To determine whether postvaccination varicella infections are caused by vaccine or wild-type virus, a simple method for distinguishing the vaccine strain from wild-type virus is required. We have developed a TaqMan real-time PCR assay to detect and differentiate wild-type virus from Oka vaccine strains of VZV. The assay utilized two fluorogenic, minor groove binding probes targeted to a single nucleotide polymorphism in open reading frame 62 that distinguishes the Oka vaccine from wild-type strains. VZV DNA could be genotyped and quantified within minutes of thermocycling completion due to real-time monitoring of PCR product formation and allelic discrimination analysis. The allelic discrimination assay was performed in parallel with two standard PCR-restriction fragment length polymorphism (RFLP) methods on 136 clinical and laboratory VZV strains from Canada, Australia, and Japan. The TaqMan assay exhibited a genotyping accuracy of 100% and, when compared to both PCR-RFLP methods, was 100 times more sensitive. In addition, the method was technically simpler and more rapid. The TaqMan assay also allows for high-throughput genotyping, making it ideal for epidemiologic study of the live attenuated varicella vaccine.

Varicella-zoster virus (VZV) is the etiological agent of varicella chicken pox and herpes zoster (HZ). Both varicella and HZ are self-limiting infections in healthy individuals but may cause more severe disease in immunocompromised hosts (2, 8, 23, 38).

A live attenuated Oka vaccine (V-Oka) strain was created in 1974 by the repeated passage of a Japanese clinical isolate in tissue culture (34). The vaccine was licensed in the United States in 1995 (2, 4) and in Canada in 1998 (27) and is currently used in many other countries (3, 40). Extensive clinical trials have shown the vaccine to be highly effective in both healthy and immunocompromised individuals (11, 19, 30, 33). However, a low incidence of superinfection with wild-type (WT) strains after immunization, termed breakthrough varicella, has been well documented (3, 10, 21, 39). Vaccine-associated rash occurs in 4 to 7% of healthy individuals (4, 40) and in up to 40% of leukemic vaccinees (10, 11). The vaccine strain does establish neuronal latency, and hence, reactivation of vaccine virus in and transmission from healthy and immunocompromised individuals is possible (11, 20, 21). As the number of vaccinees is increasing worldwide (31), the clinical management of HZ is becoming more complex. Given the fact that the vaccine virus is less pathogenic (39) and also less transmissible than WT virus (37), a timely differentiation of vaccine or WT disease would be clinically useful in situations with pregnant or immunocompromised household or hospital contacts, where prompt postexposure treatment may be indicated.

The original method used to differentiate WT and vaccine VZV was restriction fragment length polymorphism (RFLP) analysis of genomic viral DNA (14). However, this method is technically demanding and depends on virus isolation. Other more rapid methods have been devised, including single-stranded conformational polymorphism analysis (26), long PCR (35), PCR-RFLP analysis (12, 17, 25, 32), and LightCycler real-time PCR (25, 36). Of these methods, PCR-RFLP is the most widely used; however, these protocols require postamplification manipulation and are technically involved. In contrast, differentiation of WT and vaccine strains by a TaqMan real-time allelic discrimination system eliminates the need for postamplification steps and is less technically demanding and more rapid than conventional PCR. This report describes the use of TaqMan real-time allelic discrimination PCR, with minor groove binding (MGB) probes, for single-tube detection and genotyping of VZV DNA. The MGB molecules effectively raise the melting temperature of oligonucleotides by binding to the minor groove of template DNA (16), allowing use of shorter probes for real-time PCR. Thus, in an allelic discrimination assay, a single base mismatch between the template and the shorter MGB probe causes more destabilization than would a single base mismatch with a larger probe, allowing for more-accurate single nucleotide polymorphism (SNP) detection.

MATERIALS AND METHODS

Viral strains and DNA isolation. A total of 144 clinical and laboratory VZV strains were available for testing. Of these samples, 8 isolates did not amplify by any of the three PCR methods and were not included in subsequent analysis. The samples consisted of 49 isolates and 11 vesicular swabs from the virology laboratory at the Children and Women’s Health Center of British Columbia (Van-
couver, British Columbia, Canada), 22 isolates from St. Paul’s Hospital (Chris Sherlock, Vancouver, British Columbia, Canada), 51 isolates from the British Columbia Centre for Disease Control (Gail McNab, Vancouver, British Columbia, Canada), 8 isolates from the Prince of Wales Hospital (William Rawlinson, Sydney, New South Wales, Australia), the Varicella-Oka strain (Merck, Kirkland, Quebec, Canada), and the parental Oka (P-Oka) strain from Anne Ger- shon (Columbia University, New York, N.Y.). In addition, a vesicular scraping from a vaccinated 2-year-old girl was collected from the dermatology clinic of British Columbia Children’s Hospital. Isolates were collected between 1994 and 2003 (excluding the P-Oka strain, which was isolated in 1974) from cases of both HZ (n = 128) and VZ (n = 7). For clinical specimens and isolates, DNA was extracted from 200 μl of the sample with a QIAamp DNA mini kit (QiaGen, Valencia, Calif.) per the manufacturer’s instructions. DNA was eluted in 100 μl of buffer EB (10 mM Tris-Cl, pH 8.5) and was stored at −20°C until use.

**RFLP analysis.** Two RFLP methods were carried out on all samples for comparison with results obtained from the TaqMan assay. The two methods have been described elsewhere (17, 24). Briefly, two sets of primers were used to amplify a 222-bp segment in open reading frame (ORF) 54 containing a BglI site and a 350-bp segment in ORF 38 containing a Psfl site. The two PCR products were then combined and digested separately with BglI and Psfl. WT viruses were generally Psfl1/BglII1 and Psfl1/BglII2, whereas the vaccine virus was identified by the Psfl1/BglII1 RFLP pattern. The second method involves amplification of a 268-bp segment that contained an SNP at position 106262 (all nucleotide positions cited are with reference to the Dumas strain) (6) in ORF 62. The amplicon was then digested with SmaI, and the vaccine-type viruses were identified by an additional SmaI site in the vaccine strain with reference to WT strains. Both PCRs were carried out in 50-μl reaction volumes with an MJ Research PTC-200 thermostyorer (Sarborgh, Ontario, Canada). GeneAmp PCR gold buffer, deoxyribonucleotide triphosphates, MgCl2, and AmpliTaq Gold DNA polymerase were purchased from Applied Biosystems (Foster City, Calif.). PCR products were subjected to electrophoresis in either 2% (ORF 38 and 54) or 4% (ORF 62) agarose gels and visualized by ethidium bromide staining.

**PCR standards for real-time PCR.** Two primers (forward, 5’-ATC CGG TGG ACA CAC AAG AAG-3’; reverse, 5’-AGG CTA TGA GCC GTC GAT AGG-3’; H11001) were used to amplify a 215-bp segment flanking the amplon used for real-time PCR analysis. The PCR product obtained was purified with the QIAquick PCR clean-up kit (QiaGen) and then cloned into the pCR2.1 TOPO vector (Invitrogen, Carlsbad, Calif.) with the TOPO TA cloning kit (Invitrogen). The plasmid was extracted with the QiAprep plasmid mini kit (QiaGen). The plasmid was quantified by spectrophotometry, diluted in Tris-EDTA buffer, and stored at −80°C until use.

**Real-time PCR.** Two primers were designed to amplify a 62-bp product encompassing an SNP at position 107252 (forward primer, VZ62TF, 5’-TCC TAC AGA GTC GCC CGT TGC TGC CTC-3’; reverse primer, VZ225RF, 5’-GCC ACC ACA GAT GAT CAG-3’). Two fluorescent MGB probes were designed with different fluorescent dyes to allow single-tube genotyping. One probe was targeted to WT strains (WT-VZ62T, 5’-VIC-ITG CCG TGC TGC TGC C-3’) and one was targeted to V-Oka strains (V-Oka, 5’-VIC-ITG CCG TGC TGC C-3’). The amplicon was then digested with SmaI, and the vaccine-type viruses were identified by an additional SmaI site in the vaccine strain with reference to WT strains. Both PCRs were carried out in 50-μl reaction volumes with an MJ Research PTC-200 thermostyorer (Sarborgh, Ontario, Canada). GeneAmp PCR gold buffer, deoxyribonucleotide triphosphates, MgCl2, and AmpliTaq Gold DNA polymerase were purchased from Applied Biosystems (Foster City, Calif.). PCR products were subjected to electrophoresis in either 2% (ORF 38 and 54) or 4% (ORF 62) agarose gels and visualized by ethidium bromide staining.

**DISCUSSION**

PCR-RFLP has become the most widely used method for genotyping VZV, as this method offers comparable accuracy to the TaqMan genotyping VZV.

**RESULTS**

The P-Oka strain, the clinical isolate which was attenuated to create the V-Oka strain, was sequenced at position 107252, confirming the T-to-C transition identified in a past study (12). This SNP was chosen for the development of a TaqMan real-time PCR genotyping assay.

To assess the sensitivity of the TaqMan assay, 1 to 10⁷ plasmid copies of both WT and vaccine plasmid standards were amplified. The linear range of detection was determined to be 10⁷ to 10² plasmid copies for the WT probe and 10⁷ to 10⁵ plasmid copies for the vaccine probe (Fig. 1). The sensitivity of the TaqMan assay was also compared to that of the PCR-RFLP methods by amplifying serial dilutions of the positive-control clinical isolate DNA. Using the PCRs from both RFLP methods, bands were visible down to the 10⁵-fold dilution, whereas the TaqMan assay detected down to the 10⁴-fold dilution for both duplicates (estimated 100-fold-greater sensitivity). The TaqMan assay and two PCR-RFLP methods were used to genotype 125 Canadian strains, 8 Australian strains, the P-Oka strain, and the V-Oka strain. A representative allelic discrimination plot used to assign the genotypes is displayed in Fig. 2. The two genotypes were easily discriminated by the distribution along either the WT probe or V-Oka probe axis. Samples that fail to amplify clustered with the control samples containing no template. The results of the genotyping from the three methods are summarized in Table 1. The results from the TaqMan method corresponded with both RFLP methods for 134 of the total 135 strains tested. The one discrepancy was due to the mistyping of the P-Oka strain as vaccine by the ORF 38 and 54 method. The ORF 62 RFLP and TaqMan methods typed the P-Oka strain correctly as WT. It was thus concluded that the TaqMan method successfully genotyped all 135 strains correctly (specificity of 100%).

Following development and verification, the TaqMan assay was used to investigate a case of suspected HZ in a vaccinated individual. A 2-year-old girl presented with a 2-day history of asymmetrical skin lesions on the left arm that were increasing in number. She was otherwise healthy. There was a history of contact with chicken pox and HZ in the recent past. She was immunized with Varivax in March 2002 at 12 months of age. Neither her mother nor her pediatrician could recall the site of the immunization. Physical examination revealed erythematous papules and plaques with superimposed tiny vesicles extending from the left deltoid area to the flexor surface of the wrist.

A diagnosis of HZ involving the left C6 dermatome was confirmed by positive direct immunofluorescence performed on cells obtained by scraping the base of a vesicle. Viral culture was negative. The specimen was positive for vaccine virus by both the TaqMan method (Fig. 3) and the two RFLP methods. The eruption resolved without treatment.

The proportion of Canadian strains that were BglI+ was 25% (31 of 125), and 100% were PstI-. Seven of eight Australian isolates were PstI+/BglI-, and one isolate was type PstI/BglI-.
VZV genomic RFLP but is less complex and more sensitive (17). Although these methods require less technician time than genomic RFLP, they still require, on average, two working days to complete and require postamplification manipulations, bringing about the possibility of PCR product carryover, resulting in false-positive results. The TaqMan system has been shown to be rapid, sensitive, and accurate for the detection of many viruses (5, 22, 28) and dispenses with post-PCR manipulations and a number of the technical problems of PCR-RFLP methods.

The genotyping results from the TaqMan assay described herein corresponded to those obtained from the two PCR-RFLP methods for 135 of the 136 strains tested. As the single discrepancy between the methods was thought to arise from mistyping by the ORF 38 and 54 RFLP method, the genotyping accuracy of the TaqMan assay was concluded to be 100%. The TaqMan method was also performed more rapidly and with a greater sensitivity than both PCR-RFLP methods used. The TaqMan method was also able to accurately quantify both WT and V-Oka VZV DNA with a linear range of detection of 10^3 to 10^7 plasmid copies/reaction.

VZV TaqMan allelic discrimination

FIG. 1. Real-time PCR plasmid standard curve for WT and V-Oka assays. Dilutions of both WT (♦) and V-Oka (■) plasmid standards ranging from 10^7 to 1 copy/reaction were amplified by the TaqMan method. The resulting C_T values were plotted as a function of the log plasmid copy number. Each data point is the average of the results for 5 replicate reactions performed simultaneously. The linear ranges of detection for the WT and V-Oka probes were 10^2 to 10^7 and 10^3 to 10^7 plasmid copies/reaction, respectively.

FIG. 2. Allelic discrimination plot of clinical isolates and V-Oka strain. DNA from clinical isolates (♦), V-Oka DNA (△), WT DNA (○), and controls containing no template (□) were amplified in duplicate by the TaqMan method. Data were plotted by using the absolute fluorescence of each reporter dye probe. In the depicted run, all samples except one which failed to amplify were identified as WT virus, and the V-Oka DNA was identified as vaccine DNA.

VOL. 42, 2004 VZV TaqMan ALLELIC DISCRIMINATION 1411

Downloaded from http://jcm.asm.org on September 7, 2017 by guest
containing nucleic acids, including PCR products, are digested by the uracil-N-glycosylase enzyme during the 50°C step.

The present assay was designed to conform to standard thermocycling conditions (40 cycles containing a 60°C annealing and extension step), allowing the assay to be performed simultaneously with other assays, making it ideal in a clinical laboratory where numerous assays for different pathogens are being performed.

In PCR-RFLP methods, much of the time needed is devoted to postamplification steps: verifying the presence of PCR product by gel electrophoresis, restriction endonuclease digestion, and restriction pattern visualization by gel electrophoresis. The TaqMan method, by contrast, is less time-consuming because analysis of amplification can be done within minutes of thermocycling completion with the SDS software. To increase the throughput of the method for genotyping, thermocycling can be performed on several traditional thermocyclers and a 6-min post-PCR read can be done on the ABI Prism machine. This allows for an extremely high throughput with either the 96- or 384-well format. Thus, the assay is limited largely by the time required for DNA extraction; using the presently described procedure, up to 36 samples could be extracted, amplified on the ABI Prism machine in duplicate, quantified, and genotyped by one technician in ~6 h.

Our real-time VZV PCR assay will allow the sensitive and robust detection of the viral genome in clinically important specimens, such as cerebrospinal fluid and blood, aiding in the management of patients with cerebral or severe systemic VZV disease where antiviral treatment may be necessary. In addition to early viral detection, TaqMan PCR can be used to determine viral load and is thus valuable for monitoring disseminated disease progression and response to antiviral therapy in clinical and research settings. This approach has been successfully used for a number of viruses including VZV, Epstein-Barr virus, cytomegalovirus, and adenovirus (1, 7, 9). As demonstrated by the plasmid standard curve in Fig. 1, our assay is capable of quantifying VZV DNA and could be used for the mentioned applications, if desired.

Disease caused by V-Oka infection is milder than that caused by WT strains (39), and the virus is also less transmissible (37). Therefore, in a hospital setting, the timely distinction of WT and vaccine virus provides a valuable guide to the management of exposed immunocompromised or pregnant patients, for whom postexposure prophylaxis may be indicated. Since continuing epidemiological information about the frequency and seriousness of vaccine-related illness will provide baseline data for ongoing modifications of infection control guidelines in the hospital setting, the effective monitoring of adverse effects by real-time PCR would benefit patient management (31).

The success of the TaqMan method relies on the detection of a single base substitution of a C to a T at position 107252 in the V-Oka strain. It is possible that a subset of WT strains exist which carry the same V-Oka SNP or vice versa. However, from the 134 strains tested, it initially appears that the WT strains do not contain the SNP. As for V-Oka preparations containing the WT sequence, the SNP at position 107252 results in an amino acid substitution of a serine for a glycine in the V-Oka IE62, an immediate-early transcriptional activator. The activity of the V-Oka IE62 has been shown to be significantly lower than that of P-Oka IE62 in vitro (12), suggesting that altered IE62 function is selected for during vaccine pro-

---

**FIG. 3.** Allelic discrimination plot of VZV DNA isolated from zoster lesions in a vaccinated individual. DNA was extracted from a vesicle scraping obtained from a vaccinated individual with HZ. Specimen DNA from two DNA extractions (○), V-Oka DNA (△), WT DNA controls (□), and controls containing no template (□) were amplified in duplicate by the TaqMan method. Data were plotted by using the absolute fluorescence of each reporter dye probe. The clinical VZV DNA specimen clustered with the V-Oka DNA and was identified as vaccine DNA.

---

**TABLE 1.** Comparison of TaqMan genotyping method to two RFLP methods

<table>
<thead>
<tr>
<th>Source</th>
<th>Sample type</th>
<th>n</th>
<th>Restriction enzyme site in ORF:</th>
<th>TaqMan genotyping result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Merck</td>
<td>V-Oka (Varivax)</td>
<td>1</td>
<td>PstI® BglI® SmalI®</td>
<td>Vaccine</td>
</tr>
<tr>
<td>Japan</td>
<td>P-Oka strain</td>
<td>1</td>
<td>PstI® BglI® SmalI®</td>
<td>WT</td>
</tr>
<tr>
<td>Canada</td>
<td>Isolate</td>
<td>90</td>
<td>PstI® BglI® SmalI®</td>
<td>WT</td>
</tr>
<tr>
<td>Canada</td>
<td>Isolate</td>
<td>26</td>
<td>PstI® BglI® SmalI®</td>
<td>WT</td>
</tr>
<tr>
<td>Canada</td>
<td>Vesicle swab</td>
<td>4</td>
<td>PstI® BglI® SmalI®</td>
<td>WT</td>
</tr>
<tr>
<td>Canada</td>
<td>Vesicle scraping*</td>
<td>5</td>
<td>PstI® BglI® SmalI®</td>
<td>WT</td>
</tr>
<tr>
<td>Australia</td>
<td>Isolate</td>
<td>1</td>
<td>PstI® BglI® SmalI®</td>
<td>Vaccine</td>
</tr>
<tr>
<td>Australia</td>
<td>Isolate</td>
<td>1</td>
<td>PstI® BglI® SmalI®</td>
<td>WT</td>
</tr>
</tbody>
</table>

* Vesicular scraping was obtained from zoster-like vesicles in an immunized individual.
duction and would thus be less likely to be absent in vaccine preparations. In addition, the SNP used to design the assay appears to be stable after culture in a human host, as the VZV DNA recovered from the zoster lesions of a vaccinated individual were identified as the vaccine type by the TaqMan and PCR-RFLP methods.

Of the 125 Canadian WT strains tested, 25% were BglI+ and 100% were PstI+. This suggests, as expected, that Canadian strains are more like United States, United Kingdom, and German strains, of which 19, 20, and 6%, respectively, are BglI+ (13, 18, 29), than Japanese strains, of which 100% are BglI+ and up to 37% are PstI+ (15, 18, 24, 32). Interestingly, one Australian isolate was found to be PstI+/BglI-, a genotype that has not been previously reported.

In summary, the TaqMan assay exhibited exquisite genotyping accuracy, was highly reproducible, was more sensitive and rapid than both PCR-RFLP used, and was performed without postamplification steps, making the TaqMan method ideal for clinical and epidemiological use.

ACKNOWLEDGMENTS

We thank Anne Gershon for the generous donation of the P-Oka strain. We also thank Colleen Trombley and Mary Jane Margach for technical advice and Andrew Pollard for experimental advice.

REFERENCES